Xifaxan 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea in adults.
The draft guidance describes considerations regarding a switching study or studies intended to support a demonstration that a biological product is interchangeable with a reference product.
Alfaiate will be part of the executive management team, and will be responsible for strengthening corporate strategic functions and enhancing global marketing efforts.